Articles By Jack Cush, MD
High BMI Increases Arthritis Risk
Obesity carries many risks, now a new study in Arthritis & Rheumatology shows that higher body mass index (BMI) increases the risk for several rheumatic diseases, especially in women for both gout and psoriatic arthropathy.
Read Article
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis
A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA).
Read Article
What is Colchicine Worth? (6.23.2023)
Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?
Read Article
FDA Approves Colchicine for CV Prevention
The FDA has approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication.
Read Article
A Card-Carrying Optimist
I may be a snarky, opinionated curmudgeon, but I'm an optimist when and where it counts. And I think you should join me.
Read Article
Treatment Sequences Define Subphenotypes in RA Patients
An analysis of a large rheumatoid arthritis cohort sheds light on biologic disease-modifying anti-rheumatic drugs (bDMARDs) clustering that may be used in management, as certain clusters of b/tsDMARD correlated with disease activity over time.
Read Article
Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?
Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?
Read Article
Cancer Risk From RA, Not the Drugs
While it is known that rheumatoid arthritis (RA) patients may be at risk for certain cancers, the question is which cancers and is this modified by therapy.
Read Article
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
Read Article
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
New recommendations on imaging for crystal-induced (gout, CPPD) arthritis (CiA) were presented at EULAR 2023 in Milan.
Read Article
